CY2219B1 - Androstenone derivative - Google Patents

Androstenone derivative

Info

Publication number: CY2219B1
Authority: CY; Cyprus
Prior art keywords: androstenone; derivative; androstenone derivative
Prior art date: 1993-09-17

Application number

CY0100002A

Other languages

English (en)

Inventor

Kenneth W Batchelor

Stephen V Frye

Original Assignee

Glaxo Wellcome Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-17

Filing date

2001-01-03

Publication date

2003-04-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22407744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2219(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-03 Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc

2003-04-18 Publication of CY2219B1 publication Critical patent/CY2219B1/xx

Links

HFVMLYAGWXSTQI-QYXZOKGRSA-N 5alpha-androst-16-en-3-one Chemical class C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC[C@H]21 HFVMLYAGWXSTQI-QYXZOKGRSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CY0100002A 1993-09-17 2001-01-03 Androstenone derivative CY2219B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12328093A	1993-09-17	1993-09-17

Publications (1)

Publication Number	Publication Date
CY2219B1 true CY2219B1 (en)	2003-04-18

Family

ID=22407744

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY0100002A CY2219B1 (en)	1993-09-17	2001-01-03	Androstenone derivative
CY200400002C CY2004002I1 (el)	1993-09-17	2004-07-26	Παραγωγο ανδροστενονης

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY200400002C CY2004002I1 (el)	1993-09-17	2004-07-26	Παραγωγο ανδροστενονης

Country Status (41)

Country	Link
US (2)	US5565467A (fr)
EP (1)	EP0719278B1 (fr)
JP (1)	JP2904310B2 (fr)
KR (1)	KR100364953B1 (fr)
CN (1)	CN1057771C (fr)
AP (1)	AP494A (fr)
AT (1)	ATE162199T1 (fr)
AU (1)	AU690925B2 (fr)
BG (1)	BG62363B1 (fr)
BR (1)	BR1100329A (fr)
CA (2)	CA2170047C (fr)
CY (2)	CY2219B1 (fr)
CZ (1)	CZ286069B6 (fr)
DE (2)	DE69407978T2 (fr)
DK (1)	DK0719278T3 (fr)
EE (1)	EE03241B1 (fr)
ES (1)	ES2113127T3 (fr)
FI (1)	FI115216B (fr)
GR (1)	GR3026144T3 (fr)
HK (1)	HK1004334A1 (fr)
HR (1)	HRP940563B1 (fr)
HU (1)	HU220060B (fr)
IL (1)	IL110978A (fr)
IS (1)	IS1713B (fr)
LU (1)	LU91027I2 (fr)
MY (1)	MY119778A (fr)
NL (1)	NL300122I2 (fr)
NO (2)	NO306117B1 (fr)
NZ (1)	NZ274642A (fr)
OA (1)	OA10575A (fr)
PE (1)	PE15095A1 (fr)
PL (1)	PL180002B1 (fr)
RO (1)	RO117455B1 (fr)
RU (1)	RU2140926C1 (fr)
SA (1)	SA94150231B1 (fr)
SG (1)	SG52650A1 (fr)
SI (1)	SI0719278T1 (fr)
SK (1)	SK281869B6 (fr)
TW (1)	TW369521B (fr)
WO (1)	WO1995007927A1 (fr)
ZA (2)	ZA947118B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU674145B2 (en) *	1992-05-20	1996-12-12	Merck & Co., Inc.	New 17-ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5a-reductase inhibitors
DE69329933T2 (de) *	1992-10-06	2001-07-19	Merck & Co., Inc.	17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones
TW382595B (en) *	1993-10-15	2000-02-21	Merck & Co Inc	Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US5547957A (en) *	1993-10-15	1996-08-20	Merck & Co., Inc.	Method of treating androgenic alopecia with 5-α reductase inhibitors
BR9407866A (pt) *	1993-10-21	1996-10-29	Merck & Co Inc	Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica
US5817818A (en) *	1994-09-16	1998-10-06	Glaxo Wellcome Inc.	Androstenones
USRE39056E1 (en) *	1995-09-15	2006-04-04	Merck & Co, Inc.	4-Azasteroids for treatment of hyperandrogenic conditions
US5872126A (en) *	1996-09-06	1999-02-16	Merck & Co., Inc.	Methods and compositions for treating preterm labor
US5935968A (en) *	1997-03-17	1999-08-10	Merck & Co., Inc.	Methods for treating polycystic ovary syndrome
GB9717428D0 (en) *	1997-08-19	1997-10-22	Glaxo Group Ltd	Pharmaceutical composition
US5942519A (en) *	1997-10-28	1999-08-24	Merck & Co., Inc.	Prevention of precipitated acute urinary retention
EP1321146A3 (fr) *	1998-03-11	2004-06-02	Endorecherche Inc.	Inhibiteurs de la 17beta-hydroxysteroide deshydrogénase du type 5 et du type 3 ainsi que leurs méthodes d'utilisation
HUP0101809A3 (en) *	1998-03-11	2002-07-29	Endorech Inc Sainte Foy	Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use
US5998427A (en) *	1998-05-14	1999-12-07	Glaxo Wellcome Inc.	Androstenones
AU4701299A (en) *	1998-06-23	2000-01-10	Stuart R. Adler	Therapeutic applications of estrogenic carboxylic acids
AU2512800A (en) *	1999-02-03	2000-08-25	Eli Lilly And Company	Alpha1-adrenergic receptor antagonists
CN1250563C (zh)	1999-05-04	2006-04-12	斯特拉坎有限公司	雄激素糖苷及其产生雄性征的活性
US6645974B2 (en)	2001-07-31	2003-11-11	Merck & Co., Inc.	Androgen receptor modulators and methods for use thereof
CA2462456C (fr) *	2001-10-03	2010-05-04	Merck & Co., Inc.	Androstane 17-beta-carboxamides en tant que modulateurs de recepteurs d'androgenes
DK1468983T3 (da) *	2002-01-25	2008-01-07	Asahi Glass Co Ltd	Fremgangsmåde til fremstilling af 2,5-bis(trifluormethyl)nitrobenzen
MXPA04010408A (es) *	2002-04-24	2005-02-17	Boehringer Ingelheim Pharma	Combinacion farmaceutica para el tratamiento de hiperplasia prostatica benigna o para la prevencion a largo plazo de la retencion urinaria aguda.
CA2484173A1 (fr) *	2002-04-30	2003-11-13	Merck & Co., Inc.	Derives de 4-azasteroide utilises comme modulateurs du recepteur de l'androgene
US7326717B2 (en) *	2003-05-06	2008-02-05	L'oreal	Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US7022854B2 (en) *	2003-07-17	2006-04-04	Dr. Reddy's Laboratories, Limited	Forms of dutasteride and methods for preparation thereof
US20050059692A1 (en) *	2003-09-09	2005-03-17	Dr. Reddy's Laboratories Limited	Process for the preparation of 17beta-N-[2,5-bis(trifluoromethyl)phenyl] carbamoyl-4-aza-5-alpha-androst-1-en-3-one
WO2005092341A1 (fr) *	2004-03-22	2005-10-06	Ranbaxy Laboratories Limited	Therapie combinee destinee a reduire les symptomes des voies urinaires
EP1734963A4 (fr) *	2004-04-02	2008-06-18	Merck & Co Inc	Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
JP2008510811A (ja) *	2004-08-25	2008-04-10	メルクエンドカムパニーインコーポレーテッド	アンドロゲン受容体モジュレーター
US7998970B2 (en) *	2004-12-03	2011-08-16	Proteosys Ag	Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders
US20060193804A1 (en) *	2005-02-24	2006-08-31	L'oreal	Haircare use of cyclic amine derivatives
CA2602386A1 (fr) *	2005-03-25	2006-10-05	Merck & Co., Inc.	Traitement d'humains de sexe masculin par supplementation en testosterone associee a un inhibiteur de 5alpha-reductase
EP1945615A2 (fr) *	2005-11-10	2008-07-23	Dr. Reddy's Laboratories Ltd.	Préparation de dutastéride
EP1897533A1 (fr) *	2006-09-08	2008-03-12	Revotar Biopharmaceuticals AG	Utilisation de 1,6-Bis[3-(3-carboxyméthylphényl)-4-(2-alpha-D-mannopyranosyl-oxy)-phényl]hexane pour la préparation des compositions cosmétiques.
EP1946756A1 (fr) *	2007-01-17	2008-07-23	Revotar Biopharmaceuticals AG	Utilisation d'entacapone dans les compositions cosmétiques, dermatologiques et pharmaceutiques
FR2920309B1 (fr)	2007-08-28	2010-05-28	Galderma Res & Dev	Utilisation de travoprost pour traiter la chute des cheveux
US20090076057A1 (en) *	2007-09-13	2009-03-19	Protia, Llc	Deuterium-enriched dutasteride
EP2050436A1 (fr)	2007-12-21	2009-04-22	Siegfried Generics International AG	Composition pharmaceutique qui comporte de la dutastéride
AR070313A1 (es)	2008-01-03	2010-03-31	Gador Sa	Un procedimiento para preparar una forma solida y cristalina de dutasteride, una forma polimorfica del compuesto (forma iii) y una composicion farmaceutica que incluye dicha forma
FR2929117B1 (fr)	2008-03-28	2010-05-07	Oreal	Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
FR2929118B1 (fr)	2008-03-28	2010-05-07	Oreal	Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
DK2273994T3 (en)	2008-04-03	2016-02-01	Neurmedix Inc	PHARMACEUTICAL FORMS OF A MEDICINE
US20100048598A1 (en) *	2008-08-21	2010-02-25	Sateesh Kandavilli	Topical compositions comprising 5-alpha reductase inhibitors
CN101759762B (zh) *	2008-11-06	2013-03-20	天津金耀集团有限公司	4ad在制备度他雄胺中的应用
WO2011004242A2 (fr) *	2009-07-09	2011-01-13	Aurobindo Pharma Limited	Procédé amélioré de préparation du dutastéride
FR2949052B1 (fr)	2009-08-13	2015-03-27	Oreal	Procede de traitement cosmetique du cuir chevelu.
EP2468262A1 (fr)	2010-12-06	2012-06-27	Krka Tovarna Zdravil, D.D., Novo Mesto	Composition pharmaceutique contenant de la dutastéride
WO2012162776A1 (fr) *	2011-06-03	2012-12-06	Eurofarma Laboratórios S.A	Composition pharmaceutique pour le traitement de l'hyperplasie bénigne de la prostate
HU230730B1 (hu)	2011-06-30	2017-12-28	Richter Gedeon Nyrt	Eljárás (5alfa,17béta)-N-[2,5-bisz-(trifluormetil)-fenil]-3-oxo-4-aza-5-androszt-1-én-17-karbonsavamid előállítására
CN103059098B (zh) *	2011-10-24	2015-04-01	成都国为医药科技有限公司	一种度他雄胺的制备方法
US9622981B2 (en)	2011-11-17	2017-04-18	Mylan Inc.	Liquid-filled hard gel capsule pharmaceutical formulations
CN102382165B (zh) *	2011-12-02	2014-05-07	华润赛科药业有限责任公司	一种度他雄胺的制备方法
CN102532236B (zh) *	2012-01-05	2014-04-16	中国药科大学	甾体类5α-还原酶抑制剂、其制备方法及其医药用途
CN103554210A (zh) *	2012-01-05	2014-02-05	中国药科大学	甾体类5α-还原酶抑制剂、其制备方法及其医药用途
KR101976137B1 (ko)	2012-01-25	2019-05-09	한미약품 주식회사	두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법
DK2838533T3 (da)	2012-04-16	2017-11-27	Univ Case Western Reserve	Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
WO2014002015A1 (fr)	2012-06-25	2014-01-03	Ranbaxy Laboratories Limited	Composition pharmaceutique comprenant du dutastéride
CA2902335C (fr) *	2013-03-14	2021-09-14	Pellficure Pharmaceuticals, Inc.	Nouvelle therapie pour le carcinome de la prostate
CN103254268A (zh) *	2013-05-16	2013-08-21	寿光市富康化学工业有限公司	一种制备度他雄胺的工艺
BR102013020508B1 (pt)	2013-08-12	2021-01-12	Ems S/A.	Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
AU2014342811B2 (en)	2013-10-15	2019-01-03	Board Of Regents Of The University Of Texas System	Compositions and methods of modulating short-chain dehydrogenase activity
EP2949319A1 (fr)	2014-05-26	2015-12-02	Galenicum Health S.L.	Compositions pharmaceutiques comprenant un agent actif
WO2016090373A1 (fr)	2014-12-05	2016-06-09	Case Western Reserve University	Compositions et procédés de modulation de s-nitrosylation
KR101590072B1 (ko)	2014-12-23	2016-01-29	한미약품 주식회사	두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
CN113896607B (zh) *	2015-03-13	2024-04-16	陶氏环球技术有限责任公司	利用包含具有含有磷环的配体的铬络合物的催化剂的烯烃低聚反应方法
KR102503428B1 (ko)	2015-12-22	2023-02-24	한미약품 주식회사	두타스테라이드를 포함하는 경구용 연질 캡슐 제형용 포장재
WO2017160106A2 (fr)	2016-03-16	2017-09-21	한미약품 주식회사	Complexe en capsule dure contenant du dutastéride et de la tamsulosine et son procédé de préparation
KR101716878B1 (ko)	2016-05-12	2017-03-15	주식회사 유유제약	글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
EP3548035A4 (fr)	2016-11-30	2020-07-22	Case Western Reserve University	Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
JP2020514323A (ja)	2017-02-06	2020-05-21	ケースウエスタンリザーブユニバーシティ	短鎖デヒドロゲナーゼ活性を調節する組成物と方法
KR102490397B1 (ko)	2017-09-01	2023-01-26	제이더블유중외제약 주식회사	두타스테라이드를 포함하는 고형 제제 및 이의 제조방법
KR101996597B1 (ko)	2017-10-13	2019-07-31	주식회사 유유제약	두타스테리드와 타다라필을 용해시킨 경구용 캡슐 제형의 복합제제
WO2019225924A1 (fr) *	2018-05-21	2019-11-28	(주)인벤티지랩	Microparticules comprenant du dutastéride et procédé de préparation associé
KR102281252B1 (ko) *	2018-05-21	2021-07-23	(주)인벤티지랩	두타스테라이드를 포함하는 마이크로 입자 및 이의 제조 방법
KR102921276B1 (ko)	2018-11-21	2026-02-03	케이스 웨스턴 리저브 유니버시티	단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
KR20200074759A (ko)	2018-12-17	2020-06-25	동국제약 주식회사	두타스테라이드를 함유하는 고형제제
AU2021275122A1 (en)	2020-05-20	2022-12-15	Board Of Regents Of The University Of Texas System	Compositions and methods of modulating short-chain dehydrogenase activity
WO2024144084A1 (fr) *	2022-12-26	2024-07-04	주식회사 유영제약	Composition pharmaceutique de dutastéride à dose élevée sous forme de comprimé pour administration hebdomadaire et son procédé de préparation

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4191759A (en) *	1978-04-13	1980-03-04	Merck & Co., Inc.	N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4377584A (en) *	1978-04-13	1983-03-22	Merck & Co., Inc.	4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
AU527030B2 (en) *	1978-04-13	1983-02-10	Merck & Co., Inc.	4-aza-17-substituted-5a-androstan-3-ones
US4220775A (en) *	1979-03-15	1980-09-02	Merck & Co., Inc.	Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4317817A (en) *	1979-08-27	1982-03-02	Richardson-Merrell Inc.	Novel steroid 5α-reductase inhibitors
DK465481A (da) *	1980-11-21	1982-05-22	Hoffmann La Roche	Fremgangsmaade til fremstilling af d-homostemoider
NZ211145A (en) *	1984-02-27	1988-10-28	Merck & Co Inc	4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
ATE67503T1 (de) *	1984-02-27	1991-10-15	Merck & Co Inc	17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
US5049562A (en) *	1984-02-27	1991-09-17	Merck & Co., Inc.	17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US4760071A (en) *	1984-02-27	1988-07-26	Merck & Co., Inc.	17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
GB8505862D0 (en) *	1985-03-07	1985-04-11	Erba Farmitalia	Steroidic 5alpha-reductase inhibitors
US4845104A (en) *	1986-11-20	1989-07-04	Merck & Co., Inc.	Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
EP0271219B1 (fr) *	1986-11-20	1992-07-29	Merck & Co. Inc.	Composition pharmaceutique topique contenant 17-bêta-methoxycarbonyl-4-methyl-4 -aza-5-alpha-androst-1-en-3-one
US4888336A (en) *	1987-01-28	1989-12-19	Smithkline Beckman Corporation	Steroid 5-alpha-reductase inhibitors
US5110939A (en) *	1987-01-28	1992-05-05	Smithkline Beecham Corporation	Intermediates in the preparation of steriod 5-alpha-reductase inhibitors
US4814324A (en) *	1987-03-06	1989-03-21	Merck & Co., Inc.	Sterol inhibitors of testosterone 5α-reductase
EP0285383B1 (fr) *	1987-04-03	1994-03-16	Merck & Co. Inc.	Traitement des carcinomes prostatiques avec des 17-bêta-n-monosubstitué-carbamoyl-4-aza-5-alpha-androst-1-en-ones
DE3888994T2 (de) *	1987-04-03	1994-11-03	Merck & Co Inc	Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
US4910226A (en) *	1987-04-29	1990-03-20	Smithkline Beckman Corporation	Steroid 5-alpha-reductase inhibitors
ZA883034B (en) *	1987-04-29	1989-03-29	Smithkline Beckman Corp	Steroid 5-alpha-reductase inhibitors
US5041433A (en) *	1987-04-29	1991-08-20	Smithkline Beecham Corporation	11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
NZ225100A (en) *	1987-06-29	1991-09-25	Merck & Co Inc	Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
US4954446A (en) *	1988-05-25	1990-09-04	Smithkline Beecham Corporation	Aromatic steroid 5-α-reductase inhibitors
AU627466B2 (en) *	1988-05-25	1992-08-27	Smithkline Beckman Corporation	Aromatic steroid 5-alpha-reductase inhibitors
US5237061A (en) *	1988-10-31	1993-08-17	Merck & Co., Inc.	Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US4882319A (en) *	1988-12-23	1989-11-21	Smithkline Beckman Corporation	Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4946834A (en) *	1988-12-23	1990-08-07	Smithkline Beecham Corporation	Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US5026882A (en) *	1988-12-23	1991-06-25	Smithkline Beecham Corporation	Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4970205A (en) *	1988-12-23	1990-11-13	Smithkline Beecham Corporation	Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4937237A (en) *	1988-12-23	1990-06-26	Smithkline Beckman Corporation	Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4966898A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4966897A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
CA2023157A1 (fr) *	1989-08-21	1991-02-22	Gary H. Rasmusson	17 beta-acyl-4-aza-5-alpha-androst-1-ene-3-ones utilsiables comme inhibiteurs de l'alpha-reductase
US5032586A (en) *	1989-08-24	1991-07-16	Smithkline Beecham Corporation	7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5021575A (en) *	1989-11-13	1991-06-04	Merck & Co., Inc.	Method for introducing a 1,2 double bond into azasteroids
US5100917A (en) *	1989-12-29	1992-03-31	Merrell Dow Pharmaceuticals Inc.	Novel a-nor-steroid-3-carboxylic acid derivatives
GB9002922D0 (en) *	1990-02-09	1990-04-04	Erba Carlo Spa	17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
EP0462665A3 (en) *	1990-06-20	1993-06-30	Merck & Co. Inc.	Selected 17beta-polyaroyl-4-aza-5alpha-androst-1-en-3-ones as steroidal reductase inhibitors
EP0462662A3 (en) *	1990-06-20	1992-08-19	Merck & Co. Inc.	17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
US5061802A (en) *	1990-06-20	1991-10-29	Merck & Co. Inc.	17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
EP0462664A3 (en) *	1990-06-20	1992-11-25	Merck & Co. Inc.	Specific 17beta-thiobenzoyl-4-aza-5alpha-androst-1-en-3-ones as antiandrogenic agents
US5098908A (en) *	1990-06-20	1992-03-24	Merck & Co., Inc.	17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
AU637247B2 (en) *	1990-08-01	1993-05-20	Merrell Dow Pharmaceuticals Inc.	4-amino-delta4-steroids and their use as 5alpha-reductase inhibitors
AU642757B2 (en) *	1990-08-01	1993-10-28	Merrell Dow Pharmaceuticals Inc.	4-amino-delta4, 6-steroids and their use as 5alpha-reductase inhibitors
US5318961A (en) *	1990-08-01	1994-06-07	Merrell Dow Pharmaceuticals Inc.	4-amino-Δ4-steroids and their use as 5α-reductase inhibitors
US5091534A (en) *	1990-08-27	1992-02-25	Merck & Co., Inc.	Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5120847A (en) *	1990-08-27	1992-06-09	Merck & Co., Inc.	Process for iodinating or brominating the α-methylenic carbon of a secondary amide
CA2050824A1 (fr) *	1990-09-24	1992-03-25	John M. Williams	Methode de preparation de 3-oxo-4-azaandrost-1-en-17.beta.-ones
US5061803A (en) *	1990-09-24	1991-10-29	Merck & Co., Inc.	Process for making 17-beta alkanoyl 3-oxo-4-aza-5-α-androst-1-enes
US5061801A (en) *	1990-09-24	1991-10-29	Merck & Co., Inc.	Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones
IE76452B1 (en) *	1990-10-29	1997-10-22	Sankyo Co	Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
IL101245A0 (en) *	1991-03-20	1992-11-15	Merck & Co Inc	Pharmaceutical compositions for the treatment of prostatic cancer
IL101243A (en) *	1991-03-20	1999-12-22	Merck & Co Inc	Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
WO1992018132A1 (fr) *	1991-04-17	1992-10-29	Merck & Co., Inc.	Association pharmaceutique destinee au traitement de l'hyperplasie prostatique benigne et contenant un inhibiteur de 5 alpha-reductase
GB9115676D0 (en) *	1991-07-19	1991-09-04	Erba Carlo Spa	Process for the preparation of 17 beta substituted-4-aza-5 alpha-androstan-3-one derivatives
US5304562A (en) *	1991-10-09	1994-04-19	Ciba-Geigy Corporation	17β-substituted Aza-androstane derivatives
WO1993013124A1 (fr) *	1991-12-20	1993-07-08	Glaxo Inc.	Inhibiteurs de la 5-alpha-testosterone reductase
JP3164389B2 (ja) *	1991-12-25	2001-05-08	三共株式会社	４−アザステロイド類
SK137994A3 (en) *	1992-05-20	1995-04-12	Merck & Co Inc	7-beta-substituted-4-aza-5-alpha-cholestan-ons their using for production of pharmaceutical agent and pharmaceutical agent containing them
WO1993023038A1 (fr) *	1992-05-20	1993-11-25	Merck & Co., Inc.	INHIBITEURS DE 5α-REDUCTASE A BASE DE 4-AZASTEROIDES A SUBSTITUTION AMINO EN POSITION 17
ATE195129T1 (de) *	1992-05-20	2000-08-15	Merck & Co Inc	4-azasteroide als 5-alpha-reduktase
JPH07508039A (ja) *	1992-05-20	1995-09-07	メルク　エンド　カンパニー　インコーポレーテッド	４−アザステロイドのエステル誘導体
AU674145B2 (en) *	1992-05-20	1996-12-12	Merck & Co., Inc.	New 17-ester, amide, and ketone derivatives of 3-oxo-4-azasteroids as 5a-reductase inhibitors
WO1993023039A1 (fr) *	1992-05-20	1993-11-25	Merck & Co., Inc.	4-aza-5a-androstan ones substituees utilisees en tant qu'inhibitors de la 5a-reductase
US5536727A (en) *	1992-05-20	1996-07-16	Merck & Co., Inc.	17-Ethers and thioethers of 4-aza-steroids
WO1993023420A1 (fr) *	1992-05-20	1993-11-25	Merck & Co., Inc.	NOUVEAUX 4-AZA-5α-ANDROSTANE-3-ONES SUBSTITUES EN POSITION 7β EN TANT QU'INHIBITEURS DE LA 5α-REDUCTASE
DE69313114T2 (de) *	1992-05-20	1998-03-19	Merck & Co Inc	NEUE DELTA-17 UND DELTA-20 UNGESÄTIGTE UND GESATIGTE 17--g(b)-SUBSTITUIERTE-4-AZA-5-g(a)-ANDROSTAN-3-ON VERBINDUNGEN ALS INHIBITOREN VON 5-ALPHA-REDUCTASE
GB9210880D0 (en) *	1992-05-21	1992-07-08	Smithkline Beecham Corp	Compounds
UA35589C2 (uk) *	1992-05-21	2001-04-16	Андорешерш Інк.	ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
GB9216284D0 (en) *	1992-07-31	1992-09-16	Erba Carlo Spa	Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
GB9216329D0 (en) *	1992-07-31	1992-09-16	Erba Carlo Spa	17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
HU212459B (en) *	1992-10-02	1996-06-28	Richter Gedeon Vegyeszet	Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
US5278159A (en) *	1992-10-06	1994-01-11	Merck & Co., Inc.	Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
DE69329933T2 (de) *	1992-10-06	2001-07-19	Merck & Co., Inc.	17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
IL107611A0 (en) *	1992-11-18	1994-02-27	Smithkline Beecham Corp	Steroid compounds and pharmaceutical compositions containing them
AP459A (en) *	1992-12-18	1996-02-14	Glaxo Wellcome Inc	Substituted 6-azaandrostenones.
US5380728A (en) *	1993-02-10	1995-01-10	Merck & Co., Inc.	Aldehyde metabolite of 17β-N-monosubstituted-carbamoyl-4-aza-5α-a
US5438061A (en) *	1993-07-16	1995-08-01	Merck & Co., Inc.	7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW408127B (en) *	1993-09-17	2000-10-11	Glaxo Inc	Androstenones

1994
- 1994-09-03 TW TW083108127A patent/TW369521B/zh active
- 1994-09-13 IS IS4205A patent/IS1713B/is unknown
- 1994-09-14 MY MYPI94002449A patent/MY119778A/en unknown
- 1994-09-15 ZA ZA947118A patent/ZA947118B/xx unknown
- 1994-09-15 ZA ZA947119A patent/ZA947119B/xx unknown
- 1994-09-15 AP APAP/P/1994/000669A patent/AP494A/en active
- 1994-09-15 PE PE1994250737A patent/PE15095A1/es not_active Application Discontinuation
- 1994-09-16 IL IL11097894A patent/IL110978A/en active Protection Beyond IP Right Term
- 1994-09-16 SI SI9430130T patent/SI0719278T1/xx unknown
- 1994-09-16 CZ CZ1996745A patent/CZ286069B6/cs not_active IP Right Cessation
- 1994-09-16 CA CA002170047A patent/CA2170047C/fr not_active Expired - Lifetime
- 1994-09-16 CA CA002462061A patent/CA2462061A1/fr not_active Abandoned
- 1994-09-16 DK DK94929828T patent/DK0719278T3/da active
- 1994-09-16 JP JP7509391A patent/JP2904310B2/ja not_active Expired - Lifetime
- 1994-09-16 DE DE69407978T patent/DE69407978T2/de not_active Expired - Lifetime
- 1994-09-16 CN CN94193410A patent/CN1057771C/zh not_active Expired - Lifetime
- 1994-09-16 RU RU96108410A patent/RU2140926C1/ru active
- 1994-09-16 KR KR1019960701363A patent/KR100364953B1/ko not_active Expired - Lifetime
- 1994-09-16 WO PCT/US1994/010530 patent/WO1995007927A1/fr not_active Ceased
- 1994-09-16 EE EE9600130A patent/EE03241B1/xx unknown
- 1994-09-16 RO RO96-00537A patent/RO117455B1/ro unknown
- 1994-09-16 AU AU78751/94A patent/AU690925B2/en not_active Expired
- 1994-09-16 HK HK98103307A patent/HK1004334A1/en not_active IP Right Cessation
- 1994-09-16 DE DE10399022C patent/DE10399022I2/de active Active
- 1994-09-16 SK SK347-96A patent/SK281869B6/sk unknown
- 1994-09-16 PL PL94313492A patent/PL180002B1/pl unknown
- 1994-09-16 EP EP94929828A patent/EP0719278B1/fr not_active Expired - Lifetime
- 1994-09-16 AT AT94929828T patent/ATE162199T1/de active
- 1994-09-16 HU HU9600656A patent/HU220060B/hu unknown
- 1994-09-16 HR HR940563A patent/HRP940563B1/xx not_active IP Right Cessation
- 1994-09-16 SG SG1996007353A patent/SG52650A1/en unknown
- 1994-09-16 ES ES94929828T patent/ES2113127T3/es not_active Expired - Lifetime
- 1994-09-16 NZ NZ274642A patent/NZ274642A/en not_active IP Right Cessation
- 1994-10-10 SA SA94150231A patent/SA94150231B1/ar unknown
1995
- 1995-03-16 US US08/405,120 patent/US5565467A/en not_active Expired - Lifetime
1996
- 1996-03-08 BG BG100410A patent/BG62363B1/bg unknown
- 1996-03-13 OA OA60795A patent/OA10575A/en unknown
- 1996-03-15 NO NO961080A patent/NO306117B1/no not_active IP Right Cessation
- 1996-03-15 FI FI961231A patent/FI115216B/fi not_active IP Right Cessation
- 1996-08-22 US US08/708,167 patent/US5846976A/en not_active Expired - Lifetime
1997
- 1997-04-23 BR BR1100329-4A patent/BR1100329A/pt active IP Right Grant
1998
- 1998-02-12 GR GR980400317T patent/GR3026144T3/el unknown
2001
- 2001-01-03 CY CY0100002A patent/CY2219B1/xx unknown
2003
- 2003-03-07 NO NO2003003C patent/NO2003003I2/no unknown
- 2003-03-31 NL NL300122C patent/NL300122I2/nl unknown
- 2003-06-18 LU LU91027C patent/LU91027I2/fr unknown
2004
- 2004-07-26 CY CY200400002C patent/CY2004002I1/el unknown

Also Published As

Publication number	Publication date
IS1713B (is)	1998-12-30
FI961231A0 (fi)	1996-03-15
AP494A (en)	1996-05-15
ES2113127T3 (es)	1998-04-16
DE10399022I1 (de)	2004-01-15
IL110978A (en)	1999-01-26
NL300122I1 (nl)	2003-06-02
FI115216B (fi)	2005-03-31
DK0719278T3 (da)	1998-09-14
HRP940563B1 (en)	2000-10-31
ATE162199T1 (de)	1998-01-15
BR1100329A (pt)	2000-06-13
AP9400669A0 (en)	1994-10-31
FI961231L (fi)	1996-03-15
BG62363B1 (bg)	1999-09-30
HRP940563A2 (en)	1997-02-28
SK281869B6 (sk)	2001-08-06
GR3026144T3 (en)	1998-05-29
CN1057771C (zh)	2000-10-25
CA2170047C (fr)	2004-11-09
CY2004002I2 (el)	2009-11-04
DE69407978D1 (de)	1998-02-19
CA2462061A1 (fr)	1995-03-23
HU9600656D0 (en)	1996-05-28
AU7875194A (en)	1995-04-03
HUT73850A (en)	1996-09-30
JP2904310B2 (ja)	1999-06-14
NO2003003I2 (no)	2007-06-11
PL180002B1 (pl)	2000-11-30
EP0719278A1 (fr)	1996-07-03
DE69407978T2 (de)	1998-05-07
KR100364953B1 (ko)	2003-04-08
NO961080L (no)	1996-03-15
US5565467A (en)	1996-10-15
ZA947118B (en)	1995-05-26
TW369521B (en)	1999-09-11
CZ286069B6 (cs)	2000-01-12
DE10399022I2 (de)	2012-09-13
SI0719278T1 (sl)	1998-06-30
NO306117B1 (no)	1999-09-20
PL313492A1 (en)	1996-07-08
HK1004334A1 (en)	1998-11-20
JPH09502731A (ja)	1997-03-18
WO1995007927A1 (fr)	1995-03-23
HU220060B (hu)	2001-10-28
CA2170047A1 (fr)	1995-03-23
IS4205A (is)	1995-03-18
CN1131424A (zh)	1996-09-18
BG100410A (bg)	1996-09-30
PE15095A1 (es)	1995-06-04
US5846976A (en)	1998-12-08
NZ274642A (en)	1997-11-24
RU2140926C1 (ru)	1999-11-10
OA10575A (en)	2002-06-25
IL110978A0 (en)	1994-11-28
AU690925B2 (en)	1998-05-07
SA94150231B1 (ar)	2005-05-04
EE03241B1 (et)	1999-12-15
CZ74596A3 (en)	1996-09-11
NL300122I2 (nl)	2003-09-01
SG52650A1 (en)	1998-09-28
NO961080D0 (no)	1996-03-15
MY119778A (en)	2005-07-29
RO117455B1 (ro)	2002-03-29
EP0719278B1 (fr)	1998-01-14
ZA947119B (en)	1995-05-26
SK34796A3 (en)	1996-07-03
LU91027I2 (fr)	2004-04-28
CY2004002I1 (el)	2009-11-04

Publication	Publication Date	Title
GR3026144T3 (en)	1998-05-29	Androstenone derivative
IL122339A0 (en)	1998-04-05	Thiohydantoine derivatives
HU9400724D0 (en)	1994-06-28	2-thio-substituted carbapeneme derivatives
DE59407177D1 (en)	1998-12-03	2-fluorcycloyhexen-derivate
ZA945504B (en)	1996-01-26	Benzocarbocyclic derivatives
DE59408644D1 (en)	1999-09-23	Jacquardmaschine
DE59408733D1 (en)	1999-10-14	Metallhalogenidentladungslampe
AU122479S (en)	1995-01-30	Label-printer
ZA947183B (en)	1995-05-11	3-aryl-4-hydroxy-Delta3-dihydrofuranone derivatives
ZA945589B (en)	1996-01-29	2-phenylpyrrole derivatives
ZA947128B (en)	1995-05-08	Hydroxyethyl-azolyl derivatives
DE59407310D1 (en)	1998-12-24	Phenylazotriazolopyridinfarbstoffe
ZA945588B (en)	1996-01-29	2-Phenylpyrrole derivatives
GB9307610D0 (en)	1993-06-02	Deepwood special effects
GB2274282B (en)	1996-08-14	Piperazine-and piperidine-isoxazole derivatives
ZA934972B (en)	1994-02-01	21-Chloro-pregnane derivative
GB9304440D0 (en)	1993-04-21	2-acyloxycephem derivatives
GB9305831D0 (en)	1993-05-05	Auto-overflow
DE59403125D1 (en)	1997-07-17	Hohlleitermultiplexer/-demultiplexer
IL110645A0 (en)	1994-11-11	Azoxycyanobenzodioxane derivatives
GB9311613D0 (en)	1993-07-21	Thienylthiazole derivatives
HU9501250D0 (en)	1995-06-28	20-cyano-pregnan-21-oate derivative
TW319014U (en)	1997-11-01	Line-threading structure
CA72257S (en)	1993-03-04	Floorstand
CA73639S (en)	1993-12-16	Handstamp